All In Biotech

Drug Trial Radar · NCT03816163

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

393

Actual

Start

Mar 15, 2019

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer. There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself. The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study. Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part. This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2. Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not. Astellas is terminating the zolbetuximab pancreatic development program from Dec 2025 (following the final OS analysis in Oct 2025). Active subjects may remain on treatment if the investigator determines they are receiving benefit from it. The Survival follow-up period is no longer required.

Conditions

  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • zolbetuximabDrug

    Administered as an intravenous infusion.

  • nab-paclitaxelDrug

    Administered as an intravenous infusion

  • gemcitabineDrug

    Administered as an intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT) - (safety lead in)Time frame: Up to 28 days
  2. Overall Survival (OS)Time frame: Up to 79 months
  3. Safety assessed by Adverse Events (AEs)Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)
  4. Safety assessed by incidence of serious adverse events (SAE)Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)
  5. Safety assessed by incidence of treatment emergent adverse events (TEAE)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
  6. Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
  7. Number of participants with vital sign abnormalities and /or adverse events (AEs)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
  8. Number of participants with electrocardiograms (ECG) abnormalities and or adverse eventsTime frame: From first dose up to 30 days after last dose (Up to 80 months)
  9. Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse eventsTime frame: From first dose up to 30 days after last dose (Up to 80 months)

Locations

136 sites in 13 countries. Site status is shown where the registry gives one.

  • St. Joseph Heritage Medical Group

    Fullerton, California

  • TOI Clinical research

    Whittier, California

  • Midstate Medical Center

    Meriden, Connecticut

  • Lynn Cancer Institute

    Boca Raton, Florida

  • Baptist Health

    Miami, Florida

  • Cancer Treatment Centers of Atlanta

    Newnan, Georgia

  • University of Illinois at Chicago

    Chicago, Illinois

  • Norton Cancer Institute (NCI)

    Louisville, Kentucky

  • Ochsner Health System

    New Orleans, Louisiana

  • David C Pratt Cancer Center

    Creve Coeur, Missouri

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Commack

    Commack, New York

  • Memorial Sloan Kettering Westchester

    Harrison, New York

  • Northwell Health Cancer Institute

    Lake Success, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Memorial Sloan Kettering Nassau

    Uniondale, New York

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina

  • Novant Health

    Winston-Salem, North Carolina

  • Houston Methodist Hospital

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • MultiCare Regional Cancer Center - Gig Harbor

    Gig Harbor, Washington

  • Vista Oncology

    Olympia, Washington

  • Virginia Mason

    Seattle, Washington

  • Site AU61008

    Gosford, New South Wales, Australia

  • Site AU61007

    Wollongong, New South Wales, Australia

  • Site AU61005

    Fitzroy, Victoria, Australia

  • Site AU61006

    Warrnambool, Victoria, Australia

  • Site BR55009

    Centro Passo Fundo, Brazil

  • Site BR55008

    Rio Grande, Brazil

  • Site BR55004

    Santa Catarina, Brazil

  • Site BR55010

    São Paulo, Brazil

  • Site BR55011

    São Paulo, Brazil

  • Site BR55012

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site CN86001

    Beijing, China

  • Site CN86008

    Beijing, China

  • Site CN86014

    Beijing, China

  • Site CN86026

    Changchun, China

  • Site CN86009

    Chongqing, China

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.